BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-12-23: Form 8-K; Period of report 2013-12-23; Description 8.01 Other Events; Details 8.01.
- 2013-12-13: Form 8-K; Period of report 2013-12-13; Description 8.01 Other Events; Details 8.01.
- 2013-12-12: Form 8-K; Period of report 2013-12-12; Description 8.01 Other Events; Details 8.01.
- 2013-12-06: Form 8-K; Period of report 2013-12-06; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-12-23 | 8-K | 2013-12-23 | 8.01 Other Events | 8.01 On December 23, 2013, the Company issued a press release announcing that top-line data from Chien-804, the placebo-controlled, double-blind, randomized Phase 2 trial evaluating the efficacy of collagenase clostridium histolyticum (CCH) in canines with benign subcutaneous lipomas. | form8k.htm |
| 2013-12-13 | 8-K | 2013-12-13 | 8.01 Other Events | 8.01 On December 13, 2013, the Company issued a press release announcing that its partner Auxilium Pharmaceuticals, Inc. has dosed the first patient in its Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of frozen shoulder syndrome (adhesive capsulitis). | form8k.htm |
| 2013-12-12 | 8-K | 2013-12-12 | 8.01 Other Events | 8.01 On December 12, 2013, the Company issued a press release announcing that its Board of Directors has authorized the repurchase of up to $2 million of its outstanding common stock. | form8k.htm |
| 2013-12-06 | 8-K | 2013-12-06 | 8.01 Other Events | 8.01 On December 6, 2013, the Company announced that the U.S. Food & Drug Administration has approved the supplemental Biologics License Application submitted by the Company’s partner Auxilium Pharmaceuticals, Inc. (“Auxilium”) for XIAFLEX®, an in-office, biologic treatment of Peyronie’s disease. | form8k.htm |
| 2013-11-22 | 8-K | 2013-11-22 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 On November 21, 2013, the Company entered into an Agreement of Lease (the “New Lease”) with 35 Wilbur Street Associates, LLC (“New Landlord”) for the Company’s administrative headquarters located at 35 Wilbur Street, Lynbrook, New York 11563 (the “Premises”). 1.02 As previously reported, the Company had leased the Premises from WSC, as a manufacturing facility and administrative headquarters for over thirty (30) years, most recently on a month-to-month basis. | form8k.htm |
| 2013-11-19 | 8-K | 2013-11-19 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on November 19, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. 8.01 On November 18, 2013, the Company announced positive top-line data from the open label, Phase IIIb MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren’s) study evaluating XIAFLEX® for the concurrent treatment of adult Dupuytren’s contracture patients with multiple palpable cords, which was conducted by the Company’s strategic partner, Auxilium Pharmaceuticals, Inc. (“Auxilium”). | form8k.htm |
| 2013-11-12 | 8-K | 2013-11-12 | 2.02 Results of Operations and Financial Condition | 2.02 On November 12, 2013, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2013. | form8k.htm |
| 2013-10-23 | 8-K | 2013-10-23 | 8.01 Other Events | 8.01 On October 23, 2013, the Company announced that its partner, Auxilium Pharmaceuticals, Inc., has dosed the first patient in its Phase 2a study of XIAFLEX (“collagenase clostridium histolyticum” or “CCH”) for the treatment of cellulite (edematous fibrosclerotic panniculopathy). | form8k.htm |
| 2013-10-17 | 8-K | 2013-10-17 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on October 17, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-10-08 | 8-K | 2013-10-08 | 8.01 Other Events | 8.01 On October 7, 2013, the Company announced that data from multiple trials evaluating the use of XIAFLEX in adult patients with Dupuytren’s contracture with a palpable cord was presented by the Company’s partner, Auxilium Pharmaceuticals, Inc., at the 68th Annual Meeting of the American Society for Surgery of the Hand that took place in San Francisco, California, on October 3 – 5, 2013. | form8k.htm |
| 2013-10-03 | 8-K | 2013-10-03 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on October 3, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-09-03 | 8-K | 2013-09-03 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on September 3, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-08-09 | 8-K | 2013-08-09 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 6, 2013, the Compensation Committee of the Board of Directors of the Company approved an increase in the annual base salary of Mr. Thomas L. Wegman, the Company’s President and Principal Executive Officer, from $300,000 to $350,000, effective August 1, 2013. | form8k.htm |
| 2013-08-09 | 8-K | 2013-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2013, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2013. | form8k.htm |
| 2013-07-23 | 8-K | 2013-07-23 | 8.01 Other Events | 8.01 On July 23, 2013, the Company announced that a poster titled, “Biomechanical Evaluation of Human Uterine Fibroids after Exposure to Purified Clostridial Collagenase” was presented today at the Society for the Study of Reproduction 46th Annual Meeting taking place this week in Montreal, Quebec, Canada. | form8k.htm |
| 2013-07-17 | 8-K | 2013-07-17 | 8.01 Other Events | 8.01 On July 16, 2013, the Company announced that its partner, Auxilium Pharmaceuticals, Inc., has entered into a collaboration with Swedish Orphan Biovitrum AB (Sobi) for the long-term development, supply and commercialization of XIAPEX (collagenase clostridium histolyticum) for the treatment of Dupuytren's contracture. | form8k.htm |
| 2013-07-08 | 8-K | 2013-07-08 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on July 8, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-06-20 | 8-K | 2013-06-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2013 annual meeting of stockholders of the Company (the “2013 Annual Meeting”) was held on June 19, 2013. | form8k.htm |
| 2013-05-20 | 8-K | 2013-05-20 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on May 20, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-05-10 | 8-K | 2013-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2013, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2013. | form8k.htm |
| 2013-04-19 | 8-K | 2013-04-15 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in April 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-04-10 | 8-K | 2013-04-10 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on April 10, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-03-27 | 8-K | 2013-03-27 | 8.01 Other Events | 8.01 On March 26, 2013, the Company announced positive statistically significant top-line data from the Phase IIa study for XIAFLEX for the potential treatment of frozen shoulder (adhesive capsulitis), which was conducted by BioSpecifics’ strategic partner Auxilium Pharmaceuticals, Inc. (Auxilium). | form8k.htm |
| 2013-03-13 | 8-K | 2013-03-13 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on March 13, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-03-12 | 8-K | 2013-03-12 | 2.02 Results of Operations and Financial Condition | 2.02 On March 12, 2013, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2013. | form8k.htm |
| 2013-03-06 | 8-K | 2013-03-05 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on March 6, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-03-01 | 8-K | 2013-02-28 | 8.01 Other Events | 8.01 The Board of Directors of the Company has set June 19, 2013 as the date of the 2013 Annual Meeting of Stockholders (the “Annual Meeting”). | form8k.htm |
| 2013-02-05 | 8-K | 2013-02-05 | 8.01 Other Events | 8.01 On February 4, 2013, the Company announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website at www.jurology.com. | form8k.htm |
| 2013-01-22 | 8-K | 2013-01-22 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors beginning on January 22, 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2013-01-07 | 8-K | 2013-01-07 | 8.01 Other Events | 8.01 On January 7, 2013, the Company announced progress for XIAFLEX in two pipeline indications. | form8k.htm |
| 2013-01-04 | 8-K | 2013-01-04 | 7.01 Regulation FD Disclosure | 7.01 Our President, Thomas L. Wegman, will present to various investors in January 2013 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |